Life sciences company Thermo Fisher (NYSE:TMO) reported Q1 CY2026 results exceeding the market’s revenue expectations, with ...

XROI™ (Executive Reputation & Opportunity Index) is a proprietary framework developed by Clario Group. All scoring models, ...

Clario has announced a partnership with the Mobilise-D consortium to integrate digital mobility outcomes (DMOs) with its Opal wearable sensor system, offering a comprehensive assessment of patient ...

Thermo Fisher’s first quarter results received a negative market reaction, despite topping Wall Street’s revenue expectations ...

Drug research is changing and there are opportunities for growth, says Christopher Fikry, the new CEO of clinical trial tech firm Clario. Fikry, who Clario named as its new chief last month, shared ...

Simply sign up to the Health sector myFT Digest -- delivered directly to your inbox. Life sciences group Thermo Fisher has sealed an all-cash takeover of drug trial software maker Clario in a deal ...

Thermo Fisher Scientific, already a big player in providing services to the biopharmaceutical industry, is adding to its technology capabilities with the $9 billion acquisition of clinical trial ...

The fusion of Clario's innovative endpoint technologies and CellCarta's sample management expertise offers a single-vendor solution for imaging and histopathology in clinical trials, advancing ...

JCTechnology LLC introduces Clario, a native iOS app that lets users ask anything about their finances in plain English — powered by Anthropic’s Claude AI ...

XROI™ anchors a broader suite of AI-powered solutions designed to elevate leadership performance and organizational impact NEW YORK, April 27, 2026 /PRNewswire/ -- Clario Group today announced the ...